Early recognition of patients with axial spondyloarthritis—evaluation of referral strategies in primary care

Author:

Baraliakos Xenofon1ORCID,Tsiami Styliani1ORCID,Redeker Imke2ORCID,Tsimopoulos Konstantinos13,Marashi Ali1,Ruetten Sebastian3,Fedorov Kyril1,Avram Annalina1,Morzeck Doris1,Fruth Martin4ORCID,Braun Juergen1ORCID

Affiliation:

1. Rheumazentrum Ruhrgebiet Herne, Ruhr-University, Bochum

2. German Rheumatism Research Center, Berlin

3. Center for Spine Surgery and Pain Therapy, Center for Orthopedics and Traumatology, St. Anna Hospital Herne

4. Radiologie Herne, Herne, Germany

Abstract

Abstract Objective Chronic inflammatory back pain (IBP) is frequently reported in axial SpA (axSpA) but also in the general population. We evaluated a recently proposed two-step referral system for early recognition of axSpA in primary care and compare it with other combinations of symptoms and SpA-related items. Methods Consecutive chronic back pain patients ≤45 years of age answered a questionnaire and were seen by a primary care physician who decided whether HLA-B27 needed to be determined. They were then referred to a rheumatologist who made the diagnosis. Generally sticking to the two-step system with HLA-B27 as an additional option, combinations with a sensitivity ≥90% and a likelihood ratio >4 were compared. Results A total of 326 patients were included, 46 of whom were diagnosed with axSpA (14.1%). The sensitivity of the strategy was 87%, the specificity was 56.8% and the positive and negative predictive values were 24.8% and 96.4%, respectively. A ‘good response to NSAIDs’, ‘morning stiffness >30 min’ and ‘elevated C-reactive protein’ performed best, with a sensitivity of 91%, specificity of 67%, positive predictive value of 31% and negative predictive value of 98%. On that basis, only three patients had to be seen by a rheumatologist to diagnose one. Conclusion The earlier proposed referral system worked well but was outperformed by other combinations with high sensitivity and better specificity, which deserve to be prospectively studied.

Funder

Novartis Pharma

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3